生物制剂依从性对类风湿关节炎治疗达标的影响(6)
[23]Bhoi P，Bessette L，Bell MJ，Tkaczyk C，Nantel F，Maslova K.Adherence and dosing interval of subcutaneous antitumour necr-osis factor biologics among patients with inflammatory arthritis：analysis from a Canadian administrative database.BMJ Open，2017，7(9)：e015872.
[24]Poulos C，Hauber AB，Gonzalez JM，Turpcu A.Patients’willingness to trade off between the duration and frequency ofrheumatoid arthritis treatments.Arthritis Care Res(Hoboken)，2014，66(7)：1008-1015.
[25]Bulge SC，Goren A，Tandon N.Reasons for discontinuation ofsubcutaneous biologic therapy in the treatment of rheumatoidarthritis：a patient perspective.Patient Prefer Adherence，2015，9：121-131.
[26]Dehoratius RJ，Brent LH，Curtis JR，Ellis LA，Tang KL.Satisfaction with subcutaneous golimumab and its auto-injectoramong rheumatoid arthritis patients with inadequate response toAdalimumab or Etanercept.Patient.2018，11(3)：361-369.
[27]Okazaki M，Kobayashi H，Shimizu H，Ishii Y，Yajima T，Kanbori M.Safety，Effectiveness，and treatment persistence ofgolimumab in elderly patients with rheumatoid arthritis in real-world clinical practice in Japan.Rheumatol Ther，2018，5(1)：135-148.
[28]lannone F、Santo L，Anelli MG、Bucci R，Semeram A，Quarta L、D’Onofrio F，Marsico A，Carlino G，Casilli 0，Cacciapaglia F，Zuccam C，Falappone PC，Cantatore FP、Muratore M，Lapadula G.Colimumab in real-life settings：2 years drug survival and predictorsof clinical outcomes in rheumatoid arthritis，spondyloarthritis，andpsoriatic arthritis.Semin Arthritis Rheum，2017，47(1)：108-114.
[29]Zhang L，Lu GH，Ye S，Wu B，Shen Y，Li T.Treatmentadherence and disease burden of individuals with rheumatic dis-eases admitted as outpatients to a large rheumatology center inShanghai，China.Patient Prefer Adherence，2017，11：1591-1601.
(收稿日期：2019-02-20)
(本文編辑：林燕薇)
DOI：10.3969/j.issn.0253-9802.2019.05.001
基金项目：国家自然科学基金(81671612，81801606);广东省自然科学基金(2017A030313576，2017A030310236，2018A030313541);广东省医学科学技术研究基金(A2017093，A2017109)
作者单位：510120 广州，中山大学孙逸仙纪念医院风湿免疫科, 百拇医药(陈乐锋 马剑达 李谦华 戴冽)
[24]Poulos C，Hauber AB，Gonzalez JM，Turpcu A.Patients’willingness to trade off between the duration and frequency ofrheumatoid arthritis treatments.Arthritis Care Res(Hoboken)，2014，66(7)：1008-1015.
[25]Bulge SC，Goren A，Tandon N.Reasons for discontinuation ofsubcutaneous biologic therapy in the treatment of rheumatoidarthritis：a patient perspective.Patient Prefer Adherence，2015，9：121-131.
[26]Dehoratius RJ，Brent LH，Curtis JR，Ellis LA，Tang KL.Satisfaction with subcutaneous golimumab and its auto-injectoramong rheumatoid arthritis patients with inadequate response toAdalimumab or Etanercept.Patient.2018，11(3)：361-369.
[27]Okazaki M，Kobayashi H，Shimizu H，Ishii Y，Yajima T，Kanbori M.Safety，Effectiveness，and treatment persistence ofgolimumab in elderly patients with rheumatoid arthritis in real-world clinical practice in Japan.Rheumatol Ther，2018，5(1)：135-148.
[28]lannone F、Santo L，Anelli MG、Bucci R，Semeram A，Quarta L、D’Onofrio F，Marsico A，Carlino G，Casilli 0，Cacciapaglia F，Zuccam C，Falappone PC，Cantatore FP、Muratore M，Lapadula G.Colimumab in real-life settings：2 years drug survival and predictorsof clinical outcomes in rheumatoid arthritis，spondyloarthritis，andpsoriatic arthritis.Semin Arthritis Rheum，2017，47(1)：108-114.
[29]Zhang L，Lu GH，Ye S，Wu B，Shen Y，Li T.Treatmentadherence and disease burden of individuals with rheumatic dis-eases admitted as outpatients to a large rheumatology center inShanghai，China.Patient Prefer Adherence，2017，11：1591-1601.
(收稿日期：2019-02-20)
(本文編辑：林燕薇)
DOI：10.3969/j.issn.0253-9802.2019.05.001
基金项目：国家自然科学基金(81671612，81801606);广东省自然科学基金(2017A030313576，2017A030310236，2018A030313541);广东省医学科学技术研究基金(A2017093，A2017109)
作者单位：510120 广州，中山大学孙逸仙纪念医院风湿免疫科, 百拇医药(陈乐锋 马剑达 李谦华 戴冽)